Norbert Sommer
Research Subjects
Research Interests
Norbert Sommer has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Anna Spengler
Clinical Neuroimmunology Group Department of Neurology Philipps University Baldingerstrasse 1 D‐35043 Marburg Germany
1 shared publication- Björn Tackenberg
Department of Neurology, Philipps-University Marburg, Marburg, Germany; F. Hoffmann-La Roche Ltd, Basel, Switzerland
1 shared publication Christian Eienbröker
Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Baldingerstrasse 1, D-35043, Marburg, Germany
1 shared publicationFlorian Seitz
Clinical Neuroimmunology Group Department of Neurology Philipps University Baldingerstrasse 1 D‐35043 Marburg Germany
1 shared publicationHeike Kurz
Clinical Neuroimmunology Group Department of Neurology Philipps University Baldingerstrasse 1 D‐35043 Marburg Germany
1 shared publicationMaria Seipelt
Clinical Neuroimmunology Group Department of Neurology Philipps University Baldingerstrasse 1 D‐35043 Marburg Germany
1 shared publication
Latest Publications
- 30 October 2014
- Published by Wiley in Muscle & Nerve
- Vol. 50 (6) , 999-1004
Intravenous immunoglobulin maintenance treatment in myasthenia gravis: A randomized, controlled trial sample size simulation
Introduction: In cases of exacerbation or crisis, myasthenia gravis (MG) patients can be treated with intravenous immunoglobulin (IVIg), plasmapheresis, or immunoadsorption. However, IVIg efficacy data in maintenance treatment are sparse. Methods: We prospectively observed 16 index patients with chronic and insufficiently controlled MG under standard immunosuppressant therapy and symptomatic treatment. The IVIg treatment response was measured using changes in quantitative myasthenia gravis (QMG) score and surrogates. Based on these results, a sample size calculation for a future randomized, controlled trial (RCT) was simulated. Results: There was an enduring decline in QMG score and other parameters of about 50% under IVIg maintenance treatment. RCT sample size calculation results in 73 or 33 patients per arm to detect at least a 20% vs. 30% clinical difference in QMG score. Conclusion: We recommend using the QMG score as a primary endpoint for an RCT of IVIg maintenance for chronic MG. Muscle Nerve, 2014
- 30 October 2014
- Published by Wiley in Muscle & Nerve
- Vol. 50 (6) , 999-1004
Intravenous immunoglobulin maintenance treatment in myasthenia gravis: A randomized, controlled trial sample size simulation
Introduction: In cases of exacerbation or crisis, myasthenia gravis (MG) patients can be treated with intravenous immunoglobulin (IVIg), plasmapheresis, or immunoadsorption. However, IVIg efficacy data in maintenance treatment are sparse. Methods: We prospectively observed 16 index patients with chronic and insufficiently controlled MG under standard immunosuppressant therapy and symptomatic treatment. The IVIg treatment response was measured using changes in quantitative myasthenia gravis (QMG) score and surrogates. Based on these results, a sample size calculation for a future randomized, controlled trial (RCT) was simulated. Results: There was an enduring decline in QMG score and other parameters of about 50% under IVIg maintenance treatment. RCT sample size calculation results in 73 or 33 patients per arm to detect at least a 20% vs. 30% clinical difference in QMG score. Conclusion: We recommend using the QMG score as a primary endpoint for an RCT of IVIg maintenance for chronic MG. Muscle Nerve, 2014